Swiss National Bank Raises Position in Acceleron Pharma Inc. (XLRN)

Swiss National Bank increased its stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) by 8.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,300 shares of the biopharmaceutical company’s stock after buying an additional 3,900 shares during the period. Swiss National Bank owned 0.13% of Acceleron Pharma worth $1,529,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. raised its holdings in Acceleron Pharma by 4,559.6% during the 1st quarter. BlackRock Inc. now owns 3,674,593 shares of the biopharmaceutical company’s stock worth $97,266,000 after purchasing an additional 3,595,733 shares during the last quarter. Vanguard Group Inc. raised its holdings in Acceleron Pharma by 9.1% during the 1st quarter. Vanguard Group Inc. now owns 1,912,335 shares of the biopharmaceutical company’s stock worth $50,619,000 after purchasing an additional 158,714 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in Acceleron Pharma by 6.6% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,256,642 shares of the biopharmaceutical company’s stock worth $38,189,000 after purchasing an additional 77,683 shares during the last quarter. State Street Corp raised its holdings in Acceleron Pharma by 9.7% during the 1st quarter. State Street Corp now owns 1,034,625 shares of the biopharmaceutical company’s stock worth $27,395,000 after purchasing an additional 91,451 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in Acceleron Pharma by 2.4% during the 2nd quarter. Pictet Asset Management Ltd. now owns 664,145 shares of the biopharmaceutical company’s stock worth $16,942,000 after purchasing an additional 15,612 shares during the last quarter. Institutional investors and hedge funds own 77.35% of the company’s stock.

XLRN has been the subject of several recent research reports. Piper Jaffray Companies boosted their price objective on Acceleron Pharma from $32.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Cann reissued a “hold” rating on shares of Acceleron Pharma in a report on Friday, June 23rd. ValuEngine raised Acceleron Pharma from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Barclays PLC boosted their price objective on Acceleron Pharma from $42.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Acceleron Pharma currently has a consensus rating of “Buy” and an average price target of $42.81.

In other news, SVP Ravindra Kumar sold 13,065 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $35.41, for a total transaction of $462,631.65. Following the completion of the transaction, the senior vice president now directly owns 108,392 shares in the company, valued at $3,838,160.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin F. Mclaughlin sold 16,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total value of $614,560.00. Following the transaction, the chief financial officer now owns 50,810 shares of the company’s stock, valued at $1,951,612.10. The disclosure for this sale can be found here. Insiders have sold 66,578 shares of company stock valued at $2,518,117 over the last 90 days. 3.90% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://ledgergazette.com/2017/10/10/swiss-national-bank-raises-position-in-acceleron-pharma-inc-xlrn.html.

Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) opened at 38.78 on Tuesday. Acceleron Pharma Inc. has a 52 week low of $23.07 and a 52 week high of $41.69. The company’s market capitalization is $1.50 billion. The stock has a 50 day moving average price of $37.15 and a 200-day moving average price of $31.91.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. raised its holdings in Acceleron Pharma by 4,559.6% during the 1st quarter. BlackRock Inc. now owns 3,674,593 shares of the biopharmaceutical company’s stock worth $97,266,000 after purchasing an additional 3,595,733 shares during the last quarter. Vanguard Group Inc. raised its holdings in Acceleron Pharma by 9.1% during the 1st quarter. Vanguard Group Inc. now owns 1,912,335 shares of the biopharmaceutical company’s stock worth $50,619,000 after purchasing an additional 158,714 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in Acceleron Pharma by 6.6% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,256,642 shares of the biopharmaceutical company’s stock worth $38,189,000 after purchasing an additional 77,683 shares during the last quarter. State Street Corp raised its holdings in Acceleron Pharma by 9.7% during the 1st quarter. State Street Corp now owns 1,034,625 shares of the biopharmaceutical company’s stock worth $27,395,000 after purchasing an additional 91,451 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in Acceleron Pharma by 2.4% during the 2nd quarter. Pictet Asset Management Ltd. now owns 664,145 shares of the biopharmaceutical company’s stock worth $16,942,000 after purchasing an additional 15,612 shares during the last quarter. Institutional investors and hedge funds own 77.35% of the company’s stock.

XLRN has been the subject of several recent research reports. Piper Jaffray Companies boosted their price objective on Acceleron Pharma from $32.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Cann reissued a “hold” rating on shares of Acceleron Pharma in a report on Friday, June 23rd. ValuEngine raised Acceleron Pharma from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Barclays PLC boosted their price objective on Acceleron Pharma from $42.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Acceleron Pharma currently has a consensus rating of “Buy” and an average price target of $42.81.

In other news, SVP Ravindra Kumar sold 13,065 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $35.41, for a total transaction of $462,631.65. Following the completion of the transaction, the senior vice president now directly owns 108,392 shares in the company, valued at $3,838,160.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin F. Mclaughlin sold 16,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total value of $614,560.00. Following the transaction, the chief financial officer now owns 50,810 shares of the company’s stock, valued at $1,951,612.10. The disclosure for this sale can be found here. Insiders have sold 66,578 shares of company stock valued at $2,518,117 over the last 90 days. 3.90% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://ledgergazette.com/2017/10/10/swiss-national-bank-raises-position-in-acceleron-pharma-inc-xlrn.html.

Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) opened at 38.78 on Tuesday. Acceleron Pharma Inc. has a 52 week low of $23.07 and a 52 week high of $41.69. The company’s market capitalization is $1.50 billion. The stock has a 50 day moving average price of $37.15 and a 200-day moving average price of $31.91.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.69 million. During the same quarter last year, the business earned ($0.59) earnings per share. Acceleron Pharma’s revenue was down 3.1% compared to the same quarter last year. Equities research analysts expect that Acceleron Pharma Inc. will post ($2.69) EPS for the current year.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc. (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply